BACKGROUND: Studies of dietary ω-3 fatty acid intake and prostate cancer risk are inconsistent; however, recent large prospective studies have found increased risk of prostate cancer among men with high blood concentrations of long-chain ω-3 polyunsaturated fatty acids ([LCω-3PUFA] 20:5ω3; 22:5ω3; 22:6ω3]. This case-cohort study examines associations between plasma phospholipid fatty acids and prostate cancer risk among participants in the Selenium and Vitamin E Cancer Prevention Trial. METHODS:Case subjects were 834 men diagnosed with prostate cancer, of which 156 had high-grade cancer. The subcohort consisted of 1393 men selected randomly at baseline and from within strata frequency matched to case subjects on age and race. Proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for associations between fatty acids and prostate cancer risk overall and by grade. All statistical tests were two-sided. RESULTS: Compared with men in the lowest quartiles of LCω-3PUFA, men in the highest quartile had increased risks for low-grade (HR = 1.44, 95% CI = 1.08 to 1.93), high-grade (HR = 1.71, 95% CI = 1.00 to 2.94), and total prostate cancer (HR = 1.43, 95% CI = 1.09 to 1.88). Associations were similar for individual long-chain ω-3 fatty acids. Higher linoleic acid (ω-6) was associated with reduced risks of low-grade (HR = 0.75, 95% CI = 0.56 to 0.99) and total prostate cancer (HR = 0.77, 95% CI = 0.59 to 1.01); however, there was no dose response. CONCLUSIONS: This study confirms previous reports of increased prostate cancer risk among men with high blood concentrations of LCω-3PUFA. The consistency of these findings suggests that these fatty acids are involved in prostate tumorigenesis. Recommendations to increase LCω-3PUFA intake should consider its potential risks.
RCT Entities:
BACKGROUND: Studies of dietary ω-3 fatty acid intake and prostate cancer risk are inconsistent; however, recent large prospective studies have found increased risk of prostate cancer among men with high blood concentrations of long-chain ω-3 polyunsaturated fatty acids ([LCω-3PUFA] 20:5ω3; 22:5ω3; 22:6ω3]. This case-cohort study examines associations between plasma phospholipid fatty acids and prostate cancer risk among participants in the Selenium and Vitamin E Cancer Prevention Trial. METHODS: Case subjects were 834 men diagnosed with prostate cancer, of which 156 had high-grade cancer. The subcohort consisted of 1393 men selected randomly at baseline and from within strata frequency matched to case subjects on age and race. Proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for associations between fatty acids and prostate cancer risk overall and by grade. All statistical tests were two-sided. RESULTS: Compared with men in the lowest quartiles of LCω-3PUFA, men in the highest quartile had increased risks for low-grade (HR = 1.44, 95% CI = 1.08 to 1.93), high-grade (HR = 1.71, 95% CI = 1.00 to 2.94), and total prostate cancer (HR = 1.43, 95% CI = 1.09 to 1.88). Associations were similar for individual long-chain ω-3 fatty acids. Higher linoleic acid (ω-6) was associated with reduced risks of low-grade (HR = 0.75, 95% CI = 0.56 to 0.99) and total prostate cancer (HR = 0.77, 95% CI = 0.59 to 1.01); however, there was no dose response. CONCLUSIONS: This study confirms previous reports of increased prostate cancer risk among men with high blood concentrations of LCω-3PUFA. The consistency of these findings suggests that these fatty acids are involved in prostate tumorigenesis. Recommendations to increase LCω-3PUFA intake should consider its potential risks.
Authors: P H Gann; C H Hennekens; F M Sacks; F Grodstein; E L Giovannucci; M J Stampfer Journal: J Natl Cancer Inst Date: 1994-02-16 Impact factor: 13.506
Authors: Dima M Qato; G Caleb Alexander; Rena M Conti; Michael Johnson; Phil Schumm; Stacy Tessler Lindau Journal: JAMA Date: 2008-12-24 Impact factor: 56.272
Authors: Jorge E Chavarro; Meir J Stampfer; Hannia Campos; Tobias Kurth; Walter C Willett; Jing Ma Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-01 Impact factor: 4.254
Authors: Francesca L Crowe; Naomi E Allen; Paul N Appleby; Kim Overvad; Inge V Aardestrup; Nina F Johnsen; Anne Tjønneland; Jakob Linseisen; Rudolf Kaaks; Heiner Boeing; Janine Kröger; Antonia Trichopoulou; Assimina Zavitsanou; Dimitrios Trichopoulos; Carlotta Sacerdote; Domenico Palli; Rosario Tumino; Claudia Agnoli; Lambertus A Kiemeney; H Bas Bueno-de-Mesquita; María-Dolores Chirlaque; Eva Ardanaz; Nerea Larrañaga; José R Quirós; Maria-José Sánchez; Carlos A González; Pär Stattin; Göran Hallmans; Sheila Bingham; Kay-Tee Khaw; Sabina Rinaldi; Nadia Slimani; Mazda Jenab; Elio Riboli; Timothy J Key Journal: Am J Clin Nutr Date: 2008-11 Impact factor: 7.045
Authors: Fabio J Pacheco; Frankis G Almaguel; Whitney Evans; Leslimar Rios-Colon; Valery Filippov; Lai S Leoh; Elizabeth Rook-Arena; Melanie Mediavilla-Varela; Marino De Leon; Carlos A Casiano Journal: Inflamm Res Date: 2014-08-06 Impact factor: 4.575
Authors: Ze Liu; Mandi M Hopkins; Zhihong Zhang; Chrystal B Quisenberry; Louise C Fix; Brianna M Galvan; Kathryn E Meier Journal: J Pharmacol Exp Ther Date: 2014-12-09 Impact factor: 4.030